Ying Luan, PhD
The Ohio State University Comprehensive Cancer Center, Columbus, OHAuthored Items
John C. Byrd, MD, Alvina D. Chu, MD, Steven Coutre, MD, Tony Lin, PharmD, Ying Luan, PhD, Fan Ny, NP, Jillian Settlemire, RN
November 14, 2017 | November 2017 Vol 8, No 11
Ibrutinib, a B-cell receptor pathway inhibitor, is approved in the United States for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and allows for treatment without chemotherapy.
Last modified: June 5, 2018